300 related articles for article (PubMed ID: 19448419)
1. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
Li L; Mei TH; Zhou XD; Zhang XG
Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
[TBL] [Abstract][Full Text] [Related]
2. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
3. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
5. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
6. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival.
Zheng S; Chang Y; Hodges KB; Sun Y; Ma X; Xue Y; Williamson SR; Lopez-Beltran A; Montironi R; Cheng L
Anticancer Res; 2010 Mar; 30(3):713-8. PubMed ID: 20392988
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
8. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
9. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
Shou Y; Hirano T; Gong Y; Kato Y; Yoshida K; Ohira T; Ikeda N; Konaka C; Ebihara Y; Zhao F; Kato H
Br J Cancer; 2001 Nov; 85(11):1706-12. PubMed ID: 11742492
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
Passlick B; Sienel W; Seen-Hibler R; Wöckel W; Thetter O; Mutschler W; Pantel K
Clin Cancer Res; 2000 Oct; 6(10):3944-8. PubMed ID: 11051242
[TBL] [Abstract][Full Text] [Related]
12. [Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma].
Zhang HZ; Wei YP; Li HG; Wang M; Liu JG; Wu C
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1307-10. PubMed ID: 16982442
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer].
Fang SM; Jin X; Li Y; Wang R; Guo W; Wang N; Zhang JH
Ai Zheng; 2005 Mar; 24(3):305-10. PubMed ID: 15757531
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.
Hsu NY; Ho HC; Chow KC; Lin TY; Shih CS; Wang LS; Tsai CM
Cancer Res; 2001 Mar; 61(6):2727-31. PubMed ID: 11289154
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
Cox G; Jones JL; O'Byrne KJ
Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
[TBL] [Abstract][Full Text] [Related]
19. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V
Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome.
Stenvold H; Donnem T; Andersen S; Al-Saad S; Al-Shibli K; Busund LT; Bremnes RM
Lung Cancer; 2012 Feb; 75(2):235-41. PubMed ID: 21764478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
